Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE‑LY‑004): a single‑arm, multicentre, phase 2 trial

Rákkutatás · Mantle cell lymphoma

Zanubrutinib‑rituximab induction followed by shortened R‑DHAOx achieves a high complete‑response rate with manageable toxicity in frontline mantle cell lymphoma.

A phase II study evaluated zanubrutinib‑rituximab induction followed by shortened R‑DHAOx chemoimmunotherapy as frontline therapy for previously untreated mantle cell lymphoma. Forty‑two patients received up to 12 cycles of zanubrutinib‑rituximab (part A); responders received 4 cycles of R‑DHAOx (part B). At part A completion, the complete‑response (CR) rate was 88 % (95 % CI 74–96). At part B completion the CR rate was 92 % (95 % CI 79–98). Hematologic toxicities were common; grade 3–4 neutropenia occurred in 7 % (part A) and 49 % (part B), while thrombocytopenia occurred in 77 % of patients receiving part B. Zanubrutinib maintenance for one year was given to patients with CR after part B. The study demonstrated that this combination is efficacious and has a manageable safety profile as frontline therapy for mantle cell lymphoma.

This strategy reduces the number of chemotherapy cycles required for frontline mantle cell lymphoma, potentially lowering treatment‑related toxicity and preserving patient quality of life while maintaining high efficacy.

Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Eredeti forrás

Kapcsolódó jelek